Top Markets
Coin of the day
Homology Medicines, Inc. Homology Medicines, Inc.

Homology Medicines, Inc.

FIXX
주식 순위 #39911
Homology Medicines, Inc. is a biotechnology firm dedicated to genetic... Homology Medicines, Inc. is a biotechnology firm dedicated to genetic therapeutics, striving to enhance the well-being of patients battling rare inherited disorders. The company leverages its unique platform, which employs adeno-associated virus vectors (AAVHSCs) originating from human hematopoietic stem cells, to introduce genetic treatments directly into the body. This approach facilitates either gene therapy or nuclease-free gene editing solutions for a range of genetic ailments. Crucially, Homology's diverse collection of AAVHSCs enables the precise targeting of multiple disease-affected tissues—such as the liver, central and peripheral nervous systems, bone marrow, heart, skeletal muscles, and eyes—all from a single administration. The leading candidate in their pipeline, HMI-102, is a gene therapy undergoing the Phase 2 pheNIX clinical trial, intended for adult patients with phenylketonuria (PKU). Beyond this, their development portfolio includes HMI-103 for pediatric PKU, HMI-202 targeting metachromatic leukodystrophy, HMI-203 for mucopolysaccharidosis type II, and HMI-104 designed to address paroxysmal nocturnal hemoglobinuria. Established in 2015, Homology Medicines, Inc. maintains its corporate headquarters in Bedford, Massachusetts.
주가
$0.9347
마지막 동기화: 2024-03-25
시가총액
$300.42K
변동 (1일)
0.75%
변동 (1년)
0.00%
국가
US
거래 Homology Medicines, Inc. (FIXX)

카테고리

Homology Medicines, Inc. (FIXX)의 P/B 비율
2026 기준 P/B 비율 TTM: 0
Homology Medicines, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 0입니다. 2026년 말 기준 P/B 비율은 0였습니다.
Homology Medicines, Inc.의 P/B 비율 기록 (2026 ~ 2026)
매년 말 P/B 비율
연도 P/B 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/B 비율
회사 P/B 비율 P/B 비율 차이 국가
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE